Swiss Ebola Patient Leaves Geneva Hospital After Full Recovery
A Swiss woman who contracted Ebola while in Nigeria has been discharged from Geneva University Hospital after doctors confirmed her full recovery, bringing the country’s period of hospital treatment for the infection to a close.
The patient left the Geneva University Hospitals (HUG) on November 11, following 16 days of treatment, according to information released by the hospital and reported by the Keystone-SDA news agency. The cantonal physician authorized her discharge after the medical team confirmed that she had recovered fully.
Her departure also means Switzerland no longer has any patients hospitalized with Ebola, following the earlier release of her husband, who had been isolated as a close contact but never tested positive for the disease.
A carefully managed medical evacuation
The woman tested positive for Ebola in Nigeria on October 20. Six days later, she was flown to Switzerland aboard an air ambulance operated by Rega, the Swiss air-rescue organization.
Her husband, a Swiss diplomat working in Nigeria, travelled with her. While the patient was admitted to Geneva University Hospital for specialized treatment, her husband was transferred to University Hospital Zurich (USZ) and placed in isolation because of his close contact with an infected person.
He was subsequently released on November 4 after avoiding infection. The couple’s return was coordinated under medical precautions designed to prevent exposure during transportation and hospital care.
The Geneva hospital’s November 11 announcement confirmed the patient’s recovery and discharge but provided no additional medical details. HUG said it would not disclose further information out of respect for her privacy.
That restriction leaves important aspects of her treatment undisclosed, including the precise therapies administered and the clinical course of her illness. The hospital has, however, confirmed that its medical team considered her fully recovered before approving her departure.
Why the case attracted international attention
The infection was significant because it involved the Bundibugyo virus, a relatively rare species within the group of viruses responsible for Ebola disease.
The woman, who was born in Uganda, had spent approximately two weeks there before returning to Abuja, Nigeria. Health authorities investigated where she might have contracted the infection, but the precise source had not been established in the information available during the investigation.
Her diagnosis raised questions about possible transmission across national borders, particularly because Nigeria had not been experiencing the same level of reported Ebola activity as the Democratic Republic of Congo.
The World Health Organization (WHO) identified the Nigerian case as an imported infection reported on October 20. Its November 6 outbreak update said Nigerian authorities had identified 62 contacts for follow-up by November 3. Six had completed the required 21-day monitoring period at that point.
Investigators were still examining the woman’s travel and exposure history to establish the likely source of infection.
Switzerland’s specialist hospital arrangements
The case also demonstrated the role of Switzerland’s specialist medical facilities in managing serious infectious diseases brought into the country from abroad.
Since 2019, Geneva University Hospital and University Hospital Zurich have served as Switzerland’s reference hospitals for diseases such as Ebola. Both institutions have specialized isolation facilities and trained medical personnel to manage patients while protecting healthcare workers and other people receiving treatment.
When the couple arrived on October 26, Swiss federal authorities said the hospitals were equipped to handle the situation safely. The Federal Office of Public Health (FOPH) stated that the case did not pose a risk to the Swiss population.
Geneva’s cantonal health authorities also explained that the patient’s transportation and hospital treatment followed established national and international health protocols. The arrangements were intended to prevent exposure to the virus throughout the medical evacuation and subsequent care.
The patient’s discharge marks the end of the immediate hospital response in Switzerland. It does not, however, mean that the wider international outbreak has ended.
A continuing outbreak beyond Switzerland
The infection formed part of a wider outbreak of Bundibugyo virus disease that began in 2026 and affected several countries in Africa.
In its November 6 situation report, the WHO said the Democratic Republic of Congo remained the center of sustained transmission. As of November 3, the country had recorded 10,668 confirmed cases and 5,198 deaths across 67 health zones in eight provinces.
The figures underline the scale of the outbreak, although they refer specifically to the reported situation in the Democratic Republic of Congo rather than the number of cases in Switzerland or Nigeria.
The WHO also reported nine confirmed cases in Kenya by November 3, including two deaths. Five patients had recovered, while two remained under treatment. No new confirmed cases had been reported there since October 19, and authorities said there was no evidence of transmission outside the identified cluster.
France and Uganda, which had also reported cases earlier in the outbreak, were considered to have controlled their outbreaks by August, according to the same WHO update.
The challenge posed by the Bundibugyo strain
The particular virus involved in the outbreak presents a significant public health challenge because medical tools available for other forms of Ebola cannot automatically be assumed to work against it.
The WHO explained in guidance published on November 9 that there is no licensed vaccine specifically approved for Bundibugyo virus disease. The vaccine used against the Zaire ebolavirus species does not currently have established approval for preventing this form of the disease.
Research is underway to evaluate candidate vaccines and treatments. A clinical trial launched in the Democratic Republic of Congo in October is examining potential vaccine candidates, including products designed specifically for the Bundibugyo virus.
The absence of an approved, strain-specific vaccine makes early identification, isolation, contact tracing and infection prevention especially important. According to the WHO, the virus can spread through direct contact with the blood or other bodily fluids of an infected person, contaminated materials and certain infected animals.
Symptoms can take between two and 21 days to develop after exposure. Infected people are not considered infectious before symptoms begin, making careful monitoring of identified contacts an important part of outbreak control.
Despite the continuing transmission in parts of Africa, the WHO’s November 6 assessment advised against imposing travel or trade restrictions on countries responding to the outbreak. It instead emphasized surveillance, preparedness and cooperation between neighboring countries.
A recovery in Switzerland, but work remains
The Swiss patient’s discharge is a positive development in an outbreak that has placed considerable pressure on health authorities and medical teams in several countries. It also brings the Swiss hospital response to this particular case to a close.
However, the unresolved question of how the woman became infected in the first place remains relevant to efforts to prevent further cases. The investigation into her travel and exposure history is part of a broader effort to understand how the virus has moved between affected countries.
For Switzerland, the episode has highlighted the importance of specialist hospitals, coordinated medical evacuation and strict isolation procedures when dealing with high-risk infectious diseases.
For the countries still responding to the outbreak, the priority remains identifying infections quickly, monitoring contacts and strengthening healthcare protections.
The woman’s recovery is an important outcome for her and her family. The wider public health challenge, however, will depend on whether surveillance and containment efforts can bring the remaining chains of transmission under control.
